ATE341639T1 - Adenovirus-vermittelte gentherapie - Google Patents

Adenovirus-vermittelte gentherapie

Info

Publication number
ATE341639T1
ATE341639T1 AT99971860T AT99971860T ATE341639T1 AT E341639 T1 ATE341639 T1 AT E341639T1 AT 99971860 T AT99971860 T AT 99971860T AT 99971860 T AT99971860 T AT 99971860T AT E341639 T1 ATE341639 T1 AT E341639T1
Authority
AT
Austria
Prior art keywords
adenovirus
gene therapy
mediated gene
useful
treatment
Prior art date
Application number
AT99971860T
Other languages
English (en)
Inventor
Seppo Yla-Herttuala
Anu-Maaria Sandmair
Sami Loimas
Matti Vapalahti
Original Assignee
Ark Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10842035&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE341639(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ark Therapeutics Ltd filed Critical Ark Therapeutics Ltd
Application granted granted Critical
Publication of ATE341639T1 publication Critical patent/ATE341639T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99971860T 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie ATE341639T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9824437.9A GB9824437D0 (en) 1998-11-06 1998-11-06 Gene therapy

Publications (1)

Publication Number Publication Date
ATE341639T1 true ATE341639T1 (de) 2006-10-15

Family

ID=10842035

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971860T ATE341639T1 (de) 1998-11-06 1999-11-05 Adenovirus-vermittelte gentherapie

Country Status (18)

Country Link
US (1) US6579855B1 (de)
EP (1) EP1135513B2 (de)
JP (1) JP4733833B2 (de)
KR (1) KR20020013473A (de)
CN (1) CN1184321C (de)
AT (1) ATE341639T1 (de)
AU (1) AU749451B2 (de)
CA (1) CA2348624C (de)
CY (1) CY1106198T1 (de)
DE (1) DE69933468T3 (de)
DK (1) DK1135513T4 (de)
ES (1) ES2273521T5 (de)
GB (1) GB9824437D0 (de)
HU (1) HUP0104046A3 (de)
NO (1) NO330776B1 (de)
PL (1) PL193076B1 (de)
PT (1) PT1135513E (de)
WO (1) WO2000028059A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0910950D0 (en) 2009-06-24 2009-08-05 Ark Therapeutics Ltd Filtration
GB0916997D0 (en) 2009-09-28 2009-11-11 Ark Therapeutics Ltd Combination therapy
GB201100804D0 (en) * 2011-01-18 2011-03-02 Ark Therapeutics Ltd Drug combination
US20130296407A1 (en) * 2011-01-18 2013-11-07 Ark Therapeutics, Ltd. Combination Therapy for Cancer
JP6188728B2 (ja) 2012-02-07 2017-08-30 グローバル・バイオ・セラピューティクス・インコーポレイテッドＧｌｏｂａｌ Ｂｉｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 核酸送達の区画化方法ならびにその組成物および使用
US20160058888A1 (en) * 2013-05-08 2016-03-03 Gliotherapy Limited Treatment of Operable High-Grade Glioma With Sitimagene Ceradenovec Gene Therapy and Ganciclovir
HK1225258B (en) 2013-08-08 2017-09-08 Global Bio Therapeutics, Inc. Clamping device for minimally invasive surgery
DE102019000490A1 (de) 2019-01-23 2020-07-23 HAEMES Verwaltungsgesellschaft mbH Verwendung von Oligonukleotiden für die Behandlung von Tumoren
WO2021127487A2 (en) 2019-12-20 2021-06-24 Regeneron Pharmaceuticals, Inc. Novel il2 agonists and methods of use thereof
WO2021231447A1 (en) 2020-05-12 2021-11-18 Regeneron Pharmaceuticals, Inc. Novel il10 agonists and methods of use thereof
CN117597365A (zh) 2021-05-04 2024-02-23 再生元制药公司 多特异性fgf21受体激动剂及其应用
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
KR20240099460A (ko) 2021-11-11 2024-06-28 리제너론 파아마슈티컬스, 인크. Cd20-pd1 결합 분자 및 이의 사용 방법
KR20250148746A (ko) 2023-01-13 2025-10-14 리제너론 파아마슈티컬스, 인크. Fgfr3 결합 분자 및 그의 사용 방법
IL322055A (en) 2023-01-13 2025-09-01 Regeneron Pharma IL12 receptor agonists and methods of using them
JP2026507123A (ja) 2023-02-28 2026-02-27 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｔ細胞活性化剤およびその使用方法
EP4709756A1 (de) 2023-05-10 2026-03-18 Regeneron Pharmaceuticals, Inc. Cd20-pd1-bindende moleküle und verfahren zur verwendung davon
WO2025106469A1 (en) 2023-11-14 2025-05-22 Regeneron Pharmaceuticals, Inc. Engineered heavy chain variable domains and uses thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0662441B2 (ja) * 1986-02-18 1994-08-17 花王株式会社 抗腫瘍物質徐放性製剤
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk

Also Published As

Publication number Publication date
KR20020013473A (ko) 2002-02-20
PL349489A1 (en) 2002-07-29
ES2273521T5 (es) 2011-12-28
HUP0104046A2 (hu) 2002-01-28
DE69933468T3 (de) 2012-01-19
EP1135513B2 (de) 2011-08-10
CA2348624A1 (en) 2000-05-18
US6579855B1 (en) 2003-06-17
NO20012220D0 (no) 2001-05-04
DK1135513T3 (da) 2006-11-27
CN1325450A (zh) 2001-12-05
WO2000028059A1 (en) 2000-05-18
CN1184321C (zh) 2005-01-12
DE69933468T2 (de) 2007-01-11
EP1135513B1 (de) 2006-10-04
PT1135513E (pt) 2006-12-29
DK1135513T4 (da) 2011-11-21
JP4733833B2 (ja) 2011-07-27
NO20012220L (no) 2001-05-04
CA2348624C (en) 2012-07-31
DE69933468D1 (de) 2006-11-16
CY1106198T1 (el) 2011-06-08
GB9824437D0 (en) 1999-01-06
AU749451B2 (en) 2002-06-27
HUP0104046A3 (en) 2003-09-29
AU1385100A (en) 2000-05-29
PL193076B1 (pl) 2007-01-31
JP2002529097A (ja) 2002-09-10
NO330776B1 (no) 2011-07-11
ES2273521T3 (es) 2007-05-01
EP1135513A1 (de) 2001-09-26

Similar Documents

Publication Publication Date Title
DK1135513T3 (da) Adenovirus-medieret genterapi
DE69735643D1 (de) IL12 zur Gentherapie der Tumoren
FI970768A7 (fi) Kasvainten geeniterapiahoito endoteelisoluspesifisellä, solusyklistä r iippuvalla vaikuttavalla aineella
JO2248B1 (en) Pirazolobenzodiazepines
NO20005884D0 (no) Kombinasjonsterapi for behandling av bipolare forstyrrelser
DE60041333D1 (de) Hen prostatkrebs exprimiert wird, und deren verwendungen
NO20005885L (no) Kombinasjonsterapi for behandling av refraktær depresjon
AU3552399A (en) Recombinant poliovirus for the treatment of cancer
AU3891299A (en) Combination therapy for treatment of depression
AU1264200A (en) Use of neoangiogenesis markers for diagnosing and treating tumours by therapy
FI962114A7 (fi) Yhdistelmä-DNA-adenoviruksia syöpien geeniterapiaan
NO20006047D0 (no) Fremgangsmåte for genterapi
ZA973622B (en) Use of forms of hyaluronic acid (HA) for the treatment of cancer.
EP0896055A4 (de) Apoptosis induzierendes protein und dieses kodierendes gen
HUP0101947A3 (en) Combination for the treatment of tumors
MXPA02001204A (es) Compuestos calciliticos.
EP0666313A3 (de) Telomerase als Ziel in der Gentherapie des Krebs.
DE50011084D1 (de) Verwendung von azolen zur prävention von strahlen-induziertem hautkrebs
IS5481A (is) Samsett meðferð til meðhöndlunar á alnæmi
AU5778399A (en) Gene therapy for treatment of cancer
EP1126879A4 (de) Gentherapie zur regulation des tonus der glatten muskulatur
PT1064014E (pt) Medicamento para o impedimento ou tratamento de tumores especificos de papilomavirus
HU9700425D0 (en) Use of incubated, citrate-containing leukaemic blood-product for treating tumors
AU3329999A (en) Suicide gene therapy system for the treatment of brain tumours
DE69634993D1 (de) Verwendung von hyaluronan in gentherapie

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1135513

Country of ref document: EP

UEP Publication of translation of european patent specification

Ref document number: 1135513

Country of ref document: EP